Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review.
Psoriatic arthritis (PsA) is a destructive form of inflammatory arthritis that occurs in about one-third of patients with psoriasis. The pathogenesis of PsA includes genetic and immunological factors. A review of the currently available therapies reveals that traditional disease-modifying medications have provided only marginal relief from joint inflammation in patients with PsA, and have not been successful in controlling the disease and preventing joint damage. On the basis of current understanding of the pathogenesis of joint destruction in PsA, several new medications have been introduced, including anti-tumour necrosis factor (TNF) agents and agents that interfere with T-cell function. Most of these medications have been found to be effective in both psoriasis and PsA. Recent randomised controlled trials suggest that at least anti-TNF agents may help prevent progression of joint destruction.
Gladman
Dafna D
DD
University of Toronto, Toronto Western Research Institute, Centre for Prognosis Studies in The Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada. dafna.gladman@utoronto.ca
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006801:Humans
D018501:Antirheumatic Agents